NCT07538128 2026-04-20
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Huashan Hospital
Phase EARLY_PHASE1 Recruiting
Clinical Trials
11 trialsNCT05423210 2025-12-22
Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
Stony Brook University
Phase EARLY_PHASE1 Recruiting
NCT04857684 2025-10-01
SBRT + Atezolizumab + Bevacizumab in Resectable HCC
Massachusetts General Hospital
Phase EARLY_PHASE1 Active not recruiting
NCT03802604 2025-09-09
PROMETEO
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT04249167 2023-01-06
Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer
Mayo Clinic
Phase EARLY_PHASE1 Withdrawn
NCT04102618 2022-08-15
AWARE-1
Oncolytics Biotech
Phase EARLY_PHASE1 Terminated
NCT04630210 2022-06-15
AteBrO
Universitaire Ziekenhuizen KU Leuven
Phase EARLY_PHASE1 Withdrawn
NCT03371992 2020-03-27
NO3DEXPL
Nilogen Oncosystems
Phase EARLY_PHASE1 Unknown
NCT02463994 2019-02-08
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT03208712 2018-10-24
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Terminated